University Of Erlangen-nürnberg Medical School

This phase 2 trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab (Keytruda) helps shrink tumors in people with metastatic head and neck cancer that has spread. The study planned to enroll 115 participants, but was terminated early. Researchers measure…